Plant Name: Artemisia chinensis
Taxonomic Information:
Plant ID: NPO4347
Plant Latin Name: Artemisia chinensis
Taxonomy Genus: Artemisia
Taxonomy Family: Asteraceae
Plant External Links:
NCBI TaxonomyDB:
99046
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
ThailandTraditional Medicine System:
Geographical Distribution:
Thailand
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| PIK3CB; PIK3CA; NQO2; | |
| CA14; CA12; CA9; | |
| ESR1; | |
| PTGS2; | |
| SLC22A3; | |
| GMNN; PAX8; THPO; LMNA; SHH; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| SLC superfamily of solute carriers | SLC22A3 | Solute carrier family 22 member 3 | O75751 | CHEMBL2073673 |
| Unclassified | GMNN | Geminin | O75496 | CHEMBL1293278 |
| Unclassified | PAX8 | Paired box protein Pax-8 | Q06710 | CHEMBL2362980 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | SHH | Sonic hedgehog protein | Q15465 | CHEMBL5602 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.109E-07 | 4.592E-03 | CA12, CA14, CA9 |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 1.508E-06 | 8.400E-03 | CYP3A4, ESR1, SHH |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.929E-06 | 8.400E-03 | CYP2D6, CYP3A4 |
| BP | GO:0032501; multicellular organismal process | GO:0060523; prostate epithelial cord elongation | 1.929E-06 | 8.400E-03 | ESR1, SHH |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.096E-05 | 3.821E-04 | SHH, PAX8, PIK3CA, PIK3CB, PTGS2 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.837E-07 | 2.950E-05 | CA12, CA9, CA14 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 1.135E-05 | 3.821E-04 | PIK3CA, PIK3CB, PTGS2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 1.470E-05 | 3.821E-04 | PIK3CA, PIK3CB, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 2.422E-05 | 5.038E-04 | PIK3CA, PIK3CB, ESR1 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 4.128E-05 | 7.156E-04 | PIK3CA, PIK3CB, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 6.287E-05 | 8.676E-04 | PIK3CA, PIK3CB, ESR1 |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 6.674E-05 | 8.676E-04 | SLC22A3, PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 8.605E-05 | 9.943E-04 | PIK3CA, PIK3CB, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.060E-04 | 1.102E-03 | PIK3CA, PIK3CB, ESR1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.759E-04 | 1.663E-03 | PIK3CA, LMNA, PIK3CB |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 2.512E-04 | 2.009E-03 | PIK3CA, PIK3CB, PTGS2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 2.512E-04 | 2.009E-03 | PIK3CA, THPO, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 5.234E-04 | 3.629E-03 | PIK3CA, PIK3CB, ESR1 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 9.011E-04 | 4.666E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 4.370E-04 | 3.246E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 7.773E-04 | 4.491E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 6.625E-04 | 4.053E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 9.334E-04 | 4.666E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09154 Digestive system | hsa04973 | Carbohydrate digestion and absorption | 5.822E-04 | 3.784E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 1.034E-03 | 4.666E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.212E-03 | 4.666E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 1.103E-03 | 4.666E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 1.175E-03 | 4.666E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 1.325E-03 | 4.666E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.249E-03 | 4.666E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 1.249E-03 | 4.666E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.287E-03 | 4.666E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.444E-03 | 4.666E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.526E-03 | 4.666E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 1.526E-03 | 4.666E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.364E-03 | 4.666E-03 | CYP2D6, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 2.256E-03 | 6.175E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 2.157E-03 | 6.064E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 2.727E-03 | 6.596E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 2.513E-03 | 6.533E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04666 | Fc gamma R-mediated phagocytosis | 2.460E-03 | 6.533E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.893E-03 | 6.640E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 2.727E-03 | 6.596E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.526E-03 | 4.666E-03 | CYP2D6, CYP3A4 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 1.739E-03 | 5.168E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.920E-03 | 5.546E-03 | CYP3A4, PTGS2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04070 | Phosphatidylinositol signaling system | 2.727E-03 | 6.596E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 2.837E-03 | 6.640E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 3.007E-03 | 6.640E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 3.482E-03 | 7.087E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 3.181E-03 | 6.752E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 3.064E-03 | 6.640E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 3.064E-03 | 6.640E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 3.360E-03 | 6.989E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 3.543E-03 | 7.087E-03 | CYP2D6, PTGS2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 3.924E-03 | 7.530E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 4.188E-03 | 7.641E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 4.055E-03 | 7.530E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 4.055E-03 | 7.530E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04670 | Leukocyte transendothelial migration | 3.924E-03 | 7.530E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 4.883E-03 | 8.448E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04152 | AMPK signaling pathway | 4.323E-03 | 7.751E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 4.955E-03 | 8.448E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 4.955E-03 | 8.448E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04650 | Natural killer cell mediated cytotoxicity | 5.101E-03 | 8.542E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 5.175E-03 | 8.542E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 5.939E-03 | 9.219E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 5.782E-03 | 9.111E-03 | PIK3CA, PIK3CB |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 5.627E-03 | 9.004E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04910 | Insulin signaling pathway | 5.399E-03 | 8.773E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 6.339E-03 | 9.555E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09153 Circulatory system | hsa04261 | Adrenergic signaling in cardiomyocytes | 6.098E-03 | 9.326E-03 | PIK3CA, PIK3CB |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| NA: NA | Menopausal disorder | NA | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; PTGS2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | PIK3CA; PIK3CB; CA9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIK3CA; PTGS2; PIK3CB; NQO2; CA9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| NA: NA | Rheumatold arthritis | NA | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; NQO2; CA9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
